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Introduction
Medicinal chemists have directed significant efforts to the syn-
thesis of nucleoside and nucleotide analogues endowed with
antiviral and anticancer activities.[1] Their synthesis is not
always straightforward and often it is complicated by several
issues, such us their poor solubility in organic solvents, the
presence of several reactive functional groups, and the sus-
ceptibility of the glycosidic bond to undergo hydrolytic cleav-
age. To overcome all these problems, different chemical strat-
egies have been elaborated. Among them, chemical manipula-
tion by means of protecting groups remains a fundamental
synthetic approach to prepare nucleoside analogues. Different
protecting groups are commonly employed in nucleoside and
nucleotide chemistry including both base and acid-labile. The
triphenyl methyl group, most commonly indicated as the trityl
group is typically used to protect selectively primary, over sec-
ondary hydroxyl functions.[2] The positive charge on the alpha
carbon, stabilized by the resonance effect of three aromatic
rings makes trityl ethers acid-labile. Since its discovery one
hundred years ago, the trityl group has become a key protec-
tive group, widely used in nucleoside, oligonucleotide, peptide,
carbohydrate chemistry, and indeed in almost all other fields of
organic and bioorganic chemistry.[3] Typically, the trityl group is
introduced prior to manipulation of the structure and then re-
moved when appropriate during the synthesis. However some
recent studies indicated that trityl-containing compounds
themselves possess a certain biological activity. To some
degree, such discoveries may have been serendipitous. To the
best of our knowledge the first account reporting on a trityl
compound biologically active was in 2002 from Hernandez
et al.[4] In their studies, 5’-O-tritylthymidine (1, Figure 1) emerg-
es as a novel inhibitor of human mitochondrial thymidine
kinase. After that, several other studies described the biological
potential of nucleoside analogues bearing the trityl group.[5,6]
A series of tritylated and dimethoxytritylated analogues of se-
lected pyrimidine and purine nucleosides were synthesized
and evaluated for their in vitro inhibitory activity against two
important members of the genus Flavivirus in the Flaviviridae
family, the yellow fever (YFV) and dengue viruses (DENV).
Among all compounds tested, the 5’-O-tritylated and the 5’-O-
dimethoxytritylated 5-fluorouridine derivatives exerted potency
against YFV. Interestingly in the series of purine analogues, the
5’O, N-bis-tritylated fludarabine derivative revealed strong in-
hibitory activity against DENV at mm concentrations, however
significantly weaker potency against YFV.
Figure 1. Examples of tritylated nucleosides reported as flavivirus inhibitors.
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In particular in 2013, De Burghgraeve et al.[7] during the
screening of a large compound library aimed at recognizing
hit molecules, identified 2’,5’-bis-O-tritylated uridine (2) as a fla-
vivirus inhibitor. As a consequence, several other trityl uridine
nucleosides, including different regioisomers, were prepared
and evaluated in vitro against two important members of Fla-
viviridae family, yellow fever (YFV) and dengue (DENV) virus-
es.[8] Among the different compounds 3’,5’-bis-O-tritylated uri-
dine (3) was endowed with the best inhibitory properties (YFV
IC50=1.0 mm ; DENV IC50=1.75 mm).
[9] The finding of this lipo-
philic structure being endowed with high antiviral activity for
flaviviruses, encouraged the same authors to undertake further
research. However, modifications of the trityl groups, com-
bined with minor variations of the heterocyclic base generally
led only to weak in vitro flavivirus inhibition and in some cases
to marked in vitro cytotoxicity. From these studies, only 3’,5’-
bis-O-tritylated 5-fluoro-2’-deoxyuridine (4) showed no cellular
toxicity up to a concentration of 25 mm, while having EC50
values for YFV and DENV respectively of 1.05 mgmL¢1 and
1.2 mgmL¢1.[6a]
In the attempt to explain the mode of action of this class of
compounds, De Burghgraeve et al. undertook further investiga-
tions.[7] Their preliminary data suggested that the antiviral ac-
tivity of this class of compounds might be due to an inhibition
of the viral RNA-dependent RNA polymerase rather than to
a mechanism interfering during an early or a late stage of the
viral life cycle such as virus entry, assembly, or release.
Despite being under partial control, yellow fever case num-
bers are now increasing globally, posing a serious risk of local
epidemic outbreaks. The global incidence of dengue has also
grown dramatically in recent decades. Both viruses are now
considered global threats for the entire word population. Al-
though a safe and effective vaccine against YFV exists, there is
currently no vaccine available for dengue virus and its devel-
opment has proven to be very difficult because of the exis-
tence of multiple serotypes. With no therapeutic agent avail-
able to treat and/or prevent severe epidemics of either yellow
fever or dengue virus infections, prevention is currently limited
to vector (mosquites) control measures.[10] Therefore, there is
an obvious and urgent need for the development of effective
anti-flavivirus drugs.[11]
Based on these considerations and the interesting data re-
ported in the literature for the tritylated nucleosides, we
became interested in assessing the impact of the trityl group
on several pyrimidine nucleosides not included in the previous
studies against both YFV and DENV.
Taking into account that in different studies, hindered nu-
cleoside analogues (NAs) including 3’,5’-O-trityl derivatives of
adenine nucleoside analogues were found to elicit anti-flavivi-
rus activity to some extent,[6 g, 12] we decided to include also
a few selected purine analogues in our investigations. The
structures of the pyrimidine and purine nucleosides used in
our studies are shown in Figure 2.
Results and Discussion
Chemistry
Tritylation of nucleoside analogues has always been a relatively
straightforward procedure. Generally, it is sufficient to stir the
selected nucleosides with an excess of trityl chloride at an ele-
vated temperature (110 8C).[13] However some reports have
shown that the temperature can be as low as 80–90 8C. For
our synthesis, we followed the milder approach reported by
Van Aerschot.[8] Briefly, the selected nucleoside was treated in
anhydrous pyridine, with an excess of trityl chloride (2.8 equiv-
alents), and the resulting mixture heated at 80 8C for 18 h.
After aqueous work-up, the desired tritylated compounds were
isolated by column chromatography on silica gel. In order to
avoid decomposition of the trityl moiety, 0.5% of triethylamine
was added to the chromatographic eluent in order to neutral-
ize the silica gel acidity. Although this was not strictly necessa-
ry for trityl-bearing derivatives A–D (provided that their purifi-
cation was performed in a reasonable time), we found its use
imperative during the purification of 4,4’-dimethoxytrityl deriv-
atives (E–H). The reaction always returned compounds with
a diverse degree of tritylation (5’-, 3’-, and 2’-) depending upon
the reactivity of the nucleoside. The different regioisomers
were separated by column chromatography. The general syn-
thetic procedure for the preparation of the trityl ethers of
these compounds is summarized in Scheme 1, and complete
compound information can be found in Table 1.
In order to expand the structure–activity relationship (SAR),
and considering that flavivirus inhibition profile has been
linked to the critical requirement of bulkiness in the region be-
tween the 3’ and 5’ positions[14] we decided to synthesize also
the 4,4’-dimethoxytrityl derivatives (5–20E–H, Scheme 2,
Table 2) of nucleosides 5–20.
5’-2’-O-Bis tritylated regioisomers were distinguished from
those 5’-3’-O-bis tritylated analogues using 2D NMR experi-
ments. Correlation spectroscopy (COSY) analysis allowed the
correct assignment of each proton for all the compounds. Cou-
pling of the OH signal to either the signal of 2’ or 3’ indicated
which position is unalkylated.
Scheme 1. General synthetic methods to trityl compounds 5–24A–D. Re-
agents and conditions : a) trityl chloride (2.8 equiv), pyridine (4.5 mLmmol¢1),
80 8C, 18 h; b) trityl chloride, (2.8 equiv), DMAP (2.8 equiv), pyridine
(4.5 mLmmol¢1), 80 8C, 18 h.
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Biological evaluation
The antiviral effect of all the parent nucleosides and their cor-
responding tritylated and 4,4’-dimethoxytritylated analogues
was assessed using a cell viability assay in which Vero cells
were infected with either yellow fever (YFV) or dengue viruses
(DENV, serotype D2) and further treated with the tested com-
pounds at three different concentrations (5, 10, and 20 mm).
Cell viability was determined by measurement of the level of
ATP present seven days post infection when compared to vehi-
cle only (DMSO) controls.[15] The results are reported as per-
centage of viable cells left after the assay. Tables 3 and 4 gath-
ered only compounds exhibiting an antiviral activity and in-
clude also their CC50 values, defined as the concentration re-
quired to decrease cell growth by 50%. The toxicity of all the
tested compounds on uninfected cells was also determined in
parallel.
As expected, the parent nucleosides did not show any anti-
viral activity versus both the flaviviruses, considered in this
study.
In the series of the tritylated nucleoside analogues two com-
pounds: the 5’-O-tritylated 5-FUR derivative (6D) and the 5’-O-
tritylated thymidine derivative (1) showed a similar protective
Scheme 2. General synthetic method to 4,4’-dimethoxytrityl compounds 5–
20E–H. Reagents and conditions : a) 4,4’-dimethoxytrityl chloride, (2.8 equiv),
pyridine (4.5 mLmmol¢1), 80 8C, 18 h; b) 4,4’-dimethoxytrityl chloride,
(2.8 equiv), DMAP (2.8 equiv), pyridine (4.5 mLmmol¢1), 80 8C, 18 h.
Figure 2. Nucleoside analogues (NAs) considered for this study. RBV: ribavirin, 5-FUR: 5-fluorouridine, 5-BrU: 5-bromouridine, 4’-AzidoU: 4’-azidouridine,
AraU: 2’-b-d-arabinouridine, 3TC: lamivudine, d4T: stavudine, 5-IdU: 5-iodo-2’-deoxyuridine, 5-FUDR: 5-fluoro-2’-deoxyuridine, 2’-FdU: 2’-fluoro-2’-deoxyuri-
dine, 5-AzaC: 5-azacytidine, AZT: 4’-azidothymidine, 5-MeU: 5-methyluridine, PCV: penciclovir, 3’-dA: 3’-deoxyadenosine, BCNA: bicyclic nucleoside analogue.
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effect on the target cells, infected with YFV, when tested at
20 mm, with respectively 31% and 26% of the cells maintaining
full metabolic activity. Only a low percentage (8.6%) of YFV in-
hibition was achieved by the 5’-O-tritylated-5-Me-uridine deriv-
ative 19D, at the highest concentration tested. On the other
hand, no inhibitory properties were observed for all these
compounds (6D, 1, and 19D) in the DENV (D2) inhibition
assay at any of the concentrations tested.
The 5’,3’-bis-O-tritylated ribavirin (RBV) analogue (5B) and
the 5’-O-tritylated 2’-FdU analogue (16D) displayed some inter-
esting inhibitory activity against DENV with respectively 17%
and only 11% viable cells counted at 20 mm.
However, among all the trityl analogues, the 5’-bis-O,N-trity-
lated derivative (20D-NHTr) of the anticancer agent fludara-
bine (20) displayed the strongest anti-DENV inhibitory activity
with 72% of viable cells counted at 5 mm and 100% at both
10 mm and 20 mm. Interestingly, this compound, devoid of any
significant anti-YFV inhibitory effect, seems to selectively target
Table 1. Summary of all synthesized tritylated compounds.
Cmpd Nucleoside 5’ 3’ 2’
5A RBV (5) OTr OTr OTr
5B RBV (5) OTr OTr OH
5C RBV (5) OTr OH OTr
6B 5-FUR (6) OTr OTr OH
6C 5-FUR (6) OTr OH OTr
6D 5-FUR (6) OTr OH OH
7B 5-BrU (7) OTr OTr OH
7C 5-BrU (7) OTr OH OTr
8B 4’-AzidoU (8) OTr OTr OH
8C 4’-AzidoU (8) OTr OH OTr
8D 4’-AzidoU (8) OTr OH OH
3 Uridine (9) OTr OTr OH
2 Uridine (9) OTr OH OTr
10B AraU (10) OTr OTr OH
10C AraU (10) OTr OH OTr
10D AraU (10) OTr OH OH
11D-NHTr 3TC (11) OTr – –
12D N-acetyl-3TC (12) OTr – –
13D d4T (13) OTr – –
14D 5-IdU (14) OTr OH –
4 5-FUDR (15) OTr OTr –
15D 5-FUDR (15) OTr OH –
16B 2’-FdU (16) OTr OTr –
16D 2’-FdU (16) OTr OH –
17D 5-AzaC (17) OTr OH OH
18D AZT (18) OTr – –
19B 5-MeU (19) OTr OTr OH
19C 5-MeU (19) OTr OH OTr
19D 5-MeU (19) OTr OH OH
20B Fludarabine (20) OTr OTr OH
20D-NHTr Fludarabine(20) OTr OH OH
21B Thymidine (21) OTr OTr –
1 Thymidine (21) OTr OH –
22B-NHTr PCV (22) OTr OTr –
22B PCV (22) OTr OTr –
23C 3’-dA (23) OTr – OTr
24B BCNA (24) OTr OTr –
24D BCNA (24) OTr OH –
RBV: ribavirin, 5-FUR: 5-fluorouridine, 5-BrU: 5-bromouridine, 4’-AzidoU:
4’-azidouridine, AraU: 2’-b-d-arabinouridine, 3TC: lamivudine, d4T: stavu-
dine, 5-IdU: 5-iodo-2’-deoxyuridine, 5-FUDR: 5-fluoro-2’-deoxyuridine,
2’-FdU: 2’-fluoro-2’-deoxyuridine, 5-AzaC: 5-azacytidine, AZT: 4’-azidothy-
midine, 5-MeU: 5-methyluridine, PCV: penciclovir, 3’-dA: 3’-deoxyadeno-
sine, BCNA: bicyclic nucleoside analogue, OTr: O-trityl.
Table 2. Summary of all synthesized 4,4’-dimethoxytritylated compounds.
Cmpd Nucleoside 5’ 3’ 2’
5E RBV (5) ODMTr ODMTr ODMTr
5G RBV (5) ODMTr OH ODMTr
6F 5-FUR (6) ODMTr ODMTr OH
6G 5-FUR (6) ODMTr OH ODMTr
6H 5-FUR (6) ODMTr OH OH
8G 4’-AzidoU (8) ODMTr OH ODMTr
9G Uridine (9) ODMTr OH ODMTr
9H Uridine (9) ODMTr OH OH
10E AraU (10) ODMTr ODMTr ODMTr
10F AraU (10) ODMTr ODMTr OH
12H N-acetyl-3TC (12) ODMTr – –
15F 5-FUDR (15) ODMTr ODMTr –
15H 5-FUDR (15) ODMTr OH –
16F 2’-FdU (16) ODMTr ODMTr –
16H 2’-FdU (16) ODMTr OH –
20H Fludarabine (20) ODMTr OH OH
RBV: ribavirin, 5-FUR: 5-fluorouridine, 4’-AzidoU: 4’-azidouridine, AraU:
2’-b-d-arabinouridine, 3TC: lamivudine, 5-FUDR: 5-fluoro-2’-deoxyuridine,
2’-FdU: 2’-fluoro-2’-deoxyuridine, ODMTr: O-4,4’-dimethoxytrityl.
Table 3. Antiviral activity and toxicity of selected tritylated compounds.[a]
YFV inhibition [% Cells alive] D2 inhibition [% Cells alive] Toxicity CC50
Cmpd Nucleoside 5’ 3’ 2’ 5 mm 10 mm 20 mm 5 mm 10 mm 20 mm [mm]
5B RBV (5) OTr OTr OH 0 0 0 0 0 16.851.51 >20
6D 5-FUR (6) OTr OH OH 0 0 31.242.34 0 0 0 >20
14D 5-IdU (14) OTr OH – 0 0 0 0 0 2.470.06 >20
16D 2’-FdU (16) OTr OH – 0 0 0 0 0 10.881.44 >20
19D 5-MeU (19) OTr OH OH 0 0 8.590.85 0 0 0 >20
20D-NHTr Fludarabine (20) OTr OH OH 0 0.28 0.84 71.985.75 1001.48 1007.83 >20
21B Thymidine (21) OTr OTr – 0 0 0.950.17 0 0 0 >20
1 Thymidine (21) OTr OH – 0 1.250.03 25.771.03 0 0 0 >20
22B-NHTr PCV (22) OTr OTr – 0 0 8.090.04 0 0 0 >20
[a] Determined as an inhibition percentage of yellow fever (YFV, 17D strain of ASIBI) and dengue viruses (DENV, serotype D2). Values are given as
meansSD for n=3. RBV: ribavirin, 5-FUR: 5-fluorouridine, 5-IdU: 5-iodo-2’-deoxyuridine, 2’-FdU: 2’-fluoro-2’-deoxyuridine, 5-MeU: 5-methyluridine,
PCV: penciclovir, OTr: O-trityl.
ChemistryOpen 2016, 5, 227 – 235 www.chemistryopen.org Ó 2016 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim230
DENV. Despite being the analogue of an anticancer agent,
compound 20D showed no cytotoxicity in our assays, up to
a 20 mm.
This noncytotoxic profile was observed also for all the other
analogues considered in this work with no evidence of toxicity
at concentration up to 20 mm.
Next, the antiviral effect of dimethoxytritylation of selected
nucleoside analogues was evaluated similarly to the tritylated
congeners against YF and DEN viruses. Table 4 collects the
result for the compounds of this series showing some antiviral
activity. In particular the 5’-O-DMTr-FUR derivative (6H), and,
the 5’-O-DMTr-5-FUDR derivative (15H) emerged as the most
active compounds against YFV with 100% inhibition at 20 mm.
Compound 15H was found to retain high inhibition also at
10 mm with 95% of viable cells counted. Differently from the
5’-O-tritylated-2’-deoxy-2’-fluorouridine analogue 16D, its 5’-O-
dimethoxytrityl congener 16H had pronounced inhibitory ac-
tivity but surprisingly only against YFV (78% at 20 mm).
Intriguing results were also found for the 5’-O-dimethoxytri-
tylated-uridine analogue 9H, which showed inhibitory activity
only against YFV with an inhibition of 1% at 5 mm ; 7% at
10 mm ; and 100% at 20 mm.
All 4,4’-dimethoxytritylated compounds tested were devoid
of anti-DENV activity and were found to be not toxic at con-
centrations up to 20 mm.
As mentioned already, compounds 3 and 2 have been previ-
ously reported as relatively potent anti-YFV and anti DENV
agents.[6] In contrast, our assays revealed no potency either as
anti-YFV or anti-DENV agents. Explanation of the differing re-
sults from those reported could be found in the differing de-
tection methods used.[7] We assayed the metabolic activity of
cells, quantitating ATP, which is rapidly degraded in dying cells.
Using such an assay indicating active intracellular processes, it
is possible to dissect toxic and viral effects that lead to cells
with intact membranes but no metabolic activity; that latter
method (methylene blue dye exclusion) was used in the prior
reports. The ATP assay used here is more sensitive, indicates
both toxic and viral effects leading to the loss of metabolic ac-
tivity, and is the assay of choice to identify compounds, which
lead to increased cell survival.[14,15]
Conclusion
We herein report the synthesis of tritylated and 4,4’-dime-
thoxytritylated pyrimidine and purine nucleoside analogues
and the evaluation of their inhibitory activity against YF and
DEN viruses. The activity was reported as % of viable cells re-
sulting from treatment with our compounds after exposure to
the viruses. In the series of 38 tritylated analogues, two com-
pounds, 6D and 1, showed selective and moderate YFV inhibi-
tion (31% and 26%, respectively) at 20 mm concentration. In
the DENV inhibition assay, the tritylated fludarabine derivative
20D-NHTr displayed pronounced anti-DENV inhibitory activity,
reaching 100% of virus inhibition at a concentration of 10 mm.
Within the panel of 16 4,4’-dimethoxytritylated compounds,
five of the monosubstituted derivatives (6H, 9H, 12H, 15H,
and 16H) revealed selective anti-YFV inhibitory activity ranging
from 7 to 95% at 10 mm and from 70 to 100% at 20 mm. All
the tested compounds proved to be noncytotoxic at concen-
trations up to 20 mm.
In conclusion, our preliminary biological data support an
anti-flavivirus activity for tritylated/4,4’-dimethoxytritylated nu-
cleoside analogues. Previous studies have suggested that
these drugs might act as potential inhibitors of the DENV viral
RNA-dependent RNA polymerase (RdRp).[7] However, evidence
to unravel their mechanism of action have not been provided
yet. In fact, their structure–activity relationship remains unclear
and requires additional studies and therefore it is not possible
for us here to speculate on a possible mechanism. It might be
however that the prior identified lead impacted on cellular
metabolic processes rather than a viral target.
Experimental Section
General experimental
All solvents and reagents were used as obtained from commercial
sources unless otherwise indicated. All reactions were performed
under an argon atmosphere. The 1H and 13C NMR spectra were re-
corded on a Bruker spectrometer (Billerica, MA, USA) operating at
500 MHz for 1H and 125 MHz for 13C. CDCl3 was used as the solvent
for NMR experiments, unless otherwise stated. 1H chemical shift
values (d) are referenced to the residual nondeuterated compo-
nents of the NMR solvents (d=7.26 ppm for CHCl3, etc.). The
13C
chemical shifts (d) are referenced to CDCl3 (central peak, d=
77.0 ppm). Fluorine chemical shifts are referenced to CFCl3. Mass
Table 4. Antiviral activity and toxicity of selected 4,4’-dimethoxytritylated compounds.[a]
YFV inhibition [% Cells alive] D2 inhibition [% Cells alive] Toxicity CC50
Cmpd Nucleoside 5’ 3’ 2’ 5 mm 10 mm 20 mm 5 mm 10 mm 20 mm [mm]
6H 5-FUR (6) ODMTr OH OH 9.220.46 30.891.85 1008.68 0 0 0 >20
9H Uridine (9) ODMTr OH OH 1.060.27 7.000.98 1005.23 0 0 0 >20
12H N-acetyl-3TC (12) ODMTr – – 0 0 70.4518.31 0 0 0 >20
15H 5-FUDR (15) ODMTr OH – 0 95.1710.4 1005.4 0 0 0 >20
16H 2’-FdU (16) ODMTr OH – 0 0 77.9914.81 0 0 0 >20
[a] Determined as an inhibition percentage of yellow fever (YFV, 17D strain of ASIBI) and dengue viruses (DENV, serotype D2). Values are given as
meansSD for n=3. 5-FUR: 5-fluorouridine, 3TC: lamivudine, 5-FUDR: 5-fluoro-2’-deoxyuridine, 2’-FdU: 2’-fluoro-2’-deoxyuridine.
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spectra (MS) were measured in positive-mode electrospray ioniza-
tion (ESI). Thin-layer chromatography (TLC) was performed on silica
gel 60 F254 plastic sheets. Column chromatography was per-
formed using silica gel (35–75 mesh) or on an Isolera Biotage
system (Uppsala, Sweden). Purity of prepared compounds was de-
termined to be>95% by high-performance liquid chromatography
(HPLC)–UV analysis (Thermo HPLC connected with UV detector;
Varian Pursuit XS, 4.6 mmÕ150 mm, 5.0 mm, Palo Alto, CA, USA).
Chemistry
General Procedure 1. A mixture of a nucleoside (1.0 eqmol¢1), an
appropriate trityl chloride (2.2 eqmol¢1), and 4-dimethylaminopyri-
dine (DMAP, 2.8 moleq¢1, unless stated otherwise) in anhydrous
pyridine (4.5 mLmmol¢1) was heated at 80 8C under an argon at-
mosphere for 18 h. The reaction was quenched by addition of
MeOH (2 mLmmol¢1) at rt, and kept stirring at rt for 30 min. The
solution was then concentrated and diluted in CH2Cl2. The organic
solution was washed with saturated solution of NaHCO3 (3Õ
20 mL), and the combined aqueous layers were extracted with
CH2Cl2. Combined organic layers were dried over Na2SO4, filtered,
and concentrated under vacuum. The residue was purified by
column chromatography on silica gel (eluent system gradient
MeOH in CH2Cl2=1–3% containing 0.5% triethylamine).
Experimental data for all active compounds are reported below
and for inactive compounds in the Supporting Information.
Tritylated derivatives of ribavirin (5) were prepared according to
the general procedure 1 from 5 (0.500 g, 2.05 mmol) and trityl
chloride (1.6 g, 5.74 mmol). Column purification with a gradient of
MeOH/triethylamine (1:0.5% to 2:0.5%) in CH2Cl2 as eluent yielded
5’,3’,2’-tri-O-tritylribavirin (5A), 5’,3’-bis-O-tritylribavirin (5B) and
5’,2’-bis-O-tritylribavirin (5C).
5’,3’-Bis-O-tritylribavirin (5B) was obtained as a white solid
(0.268 g, 18%); 1H NMR (500 MHz, 25 8C, CDCl3): d=8.21 (s, 1H, H-
3), 7.43–7.38 (m, 6H, H-Ph), 7.34–7.18 (m, 24H, H-Ph), 6.64 (br s,
1H, NH2), 5.89 (d, J=3.08 Hz, 1H, H-1’), 5.66 (br s, 1H, NH2), 4.43–
4.39 (m, 1H, H-3’), 4.19–4.14 (m, 1H, H-4’), 3.61–3.56 (m, 1H, H-2’),
3.47–3.43 (m, 1H, H-5’), 3.00 (dd, J=10.9, 5.5 Hz, 1H, H-5’),
2.85 ppm (d, J=4.5 Hz, 1H, OH-2’) ; 13C NMR (125 MHz, 25 8C,
CDCl3): d=160.4 (C=O), 156.9 (C-5), 144.1 (C-3), 143.5, 143.3 (C-Ph),
128.7, 128.6, 128.3, 127.8, 127.1 (CH-Ph), 92.4 (C-1’), 88.1, 87.1
(C(Ph)3), 83.5 (C-4’), 74.3 (C-2’), 74.1 (C-3’), 64.0 ppm (C-5’) ; MS
(ES+) found: m/z 751.3 [M+Na]+ , calcd for [C46H40N4O5]: m/z
728.83 [M]; Reverse-phase HPLC (H2O/CH3CN from 90:10 to 0:100
in 30 min), flow=1 mLmin¢1, l=254 nm, tR=28.10 min.
Tritylated derivatives of 5-fluorouridine (6) were prepared accord-
ing to the general procedure 1 from 6 (0.30 g, 1.14 mmol) and
trityl chloride (1.02 g, 3.66 mmol) in pyridine (6 mL). Column chro-
matography purification using a gradient of MeOH/triethylamine
(1:0.5% to 2:0.5%) in CH2Cl2 as an eluent yielded 5’,3’-bis-O-trityl-5-
fluorouridine (6B), 5’,2’-bis-O-trityl-5-fluorouridine (6C), and 5’-O-
trityl-5-fluorouridine (6D).
5’-O-Trityl-5-fluorouridine (6D) was obtained as a white solid
(0.183 g, 32%); 1H NMR (500 MHz, 25 8C, CDCl3,): d=7.42 (d, JH¢F=
6.0 Hz, 1H, H-6), 7.22–7.20 (m, 6H, H-Ph), 7.05–7.02 (m, 6H, H-Ph),
6.98–6.95 (m, 6H, H-Ph), 5.72 (dd, J=4.5, 1.5 Hz, 1H, H-1’), 4.04 (t,
J=5.0 Hz, 1H, H-3’), 3.96 (t, J=5.0 Hz, 1H, H-2’), 3.90–3.87 (m, 1H,
H-4’), 3.30 (dd, J=11.0, 2.5 Hz, 1H, H-5’), 3.25 ppm (dd, J=11.0,
2.5 Hz, 1H, H-5’) ; 13C NMR (125 MHz, 25 8C, [D6]DMSO,): d=161.0
(d, JC¢F=22.5 Hz, C-2), 152.7 (C-4), 144.4 (d, JC¢F=241.5 Hz, C-5),
143.3 (C-Ph), 128.6, 128.3, 127.3 (CH-Ph), 123.4 (d, JC¢F=33.75 Hz,
C-6), 90.1 (C-1’), 87.5 (C(Ph)3), 84.4 (C-4’), 75.8 (C-2’), 71.0 (C-3’),
63.2 ppm (C-5’) ; MS (ES+) found: m/z 527.10 [M+Na]+ , calcd for
[C28H25FN2O6]: m/z 504.50 [M]; Reverse-phase HPLC (H2O/CH3CN
from 90:10 to 0:50 in 30 min), flow=1 mLmin¢1, l=245 nm, tR=
17.52 min.
Dimethoxytritylated derivatives of 5-fluorouridine (6) were pre-
pared according to the general procedure 1 from 6 (0.30 g,
1.14 mmol) and 4,4’-dimethoxytrityl chloride (1.24 g, 3.66 mmol,
3.2 equiv/mol) in pyridine (6 mL). Column chromatography purifica-
tion using a gradient of MeOH/triethylamine (1:0.5% to 2:0.5%) in
CH2Cl2 as an eluent yielded three products, which were further re-
purified by preparative TLC using MeOH/triethylamine (2:0.5%) in
CH2Cl2 to yield: 5’,3’-bis-O-dimethoxytrityl-5fluorouridine (6F), 5’,2’-
bis-O-dimethoxytrityl-5-fluorouridine (6G), and 5’-O-dimethoxytri-
tyl-5-fluorouridine (6H).
5’-O-Dimethoxytrityl-5-fluorouridine (6H) was obtained as a yel-
lowish solid (0.17 g, 26%); 1H NMR (500 MHz, 25 8C, [D6]DMSO,):
d=7.91 (d, JH¢F=7.0 Hz, 1H, H-6), 7.40 (dd, J=8.5, 2.5 Hz, 2H, H-
Ph), 7.33–7.23 (m, 7H, H-Ph), 6.90 (apparent d, J=8.5 Hz, 4H, H-
Ph), 5.73 (dd, J=4.0, 1.5 Hz, 1H, H-1’), 5.48 (d, J=5.0 Hz, 1H, C-2’-
OH), 5.14 (d, J=5.0 Hz, 1H, C-3’-OH), 4.14 (apparent q, J=5.0 Hz,
1H, H-2’), 4.08 (apparent q, J=5.0 Hz, 1H, H-3’), 3.98–3.96 (m, 1H,
H-4’), 3.75 (s, 6H, 2 x OCH3), 3.29 (dd, J=11.0, 3.5 Hz, 1H, H-5’),
3.19 ppm (dd, J=11.0, 3.5 Hz, 1H, H-5’) ; 13C NMR (125 MHz, 25 8C,
[D6]DMSO,): d=158.2, 158.1 (CH3O-C-Ph), 156.9 (d,
2JC¢F=26.0 Hz,
C-4), 149.8 (C-2), 144.7 (C-Ph), 139.9 (d, 1JC¢F=230.5 Hz, C-5), 135.4,
135.2 (C-Ph), 129.7, 128.9, 128.2, 127.9, 127.6, 126.7, 125.3 (CH-Ph),
124.6 (d, 2JC¢F=33.8 Hz, C-6), 113.3, 113.2 (CH-Ph), 89.0 (C-1’), 85.8
(C(Ph)3), 82.6 (C-4’), 73.2 (C-2’), 69.5 (C-3’), 63.1 (C-5’), 55.0 ppm
(OCH3) ;
19F NMR (470 MHz, 25 8C, [D6]DMSO,): d=¢167.25 ppm; MS
(ES+) found: m/z 587 [M+Na]+ , calcd for [C30H29FN2O8]: m/z
564.55 [M]; Reverse-phase HPLC (H2O/CH3CN 90:10 to 0:50 in
30 min), flow=1 mLmin¢1, l=245 nm, tR=14.85 min.
Dimethoxytritylated derivatives of uridine (9) were prepared ac-
cording to the general procedure 1 from 9 (0.150 g, 0.61 mmol),
4,4’-dimethoxytrityl chloride (0.578 g, 1.71 mmol), and DMAP
(0.209 g, 1.71 mmol) in anhydrous pyridine (10 mL). Column chro-
matography eluting with a gradient of MeOH/triethylamine
(1:0.5% to 3.5:0.5%) in CH2Cl2 as an eluent gave 5’,2’-bis-O-
dimethoxytrityluridine (9G) and 5’-dimethoxytrityluridine (9H).
5’-O-Dimethoxytrityluridine (9H) was obtained as a yellowish
solid (0.16 g, 48%); 1H NMR (500 MHz, 25 8C, CDCl3): d=8.01 (d, J=
8.0 Hz, H-6), 7.43–7.38 (m, 2H, H-Ph), 7.33–7.28 (m, 6H, H-Ph), 7.26–
7.22 (m, 1H, H-Ph), 6.89–6.82 (m, 4H, H-Ph), 5.92 (d, J=2.5 Hz, H-
1’), 5.38 (d, J=8.0 Hz, H-5), 4.44 (dd, J=6.0, 5.5 Hz, H-3’), 4.36 (dd,
J=5.0, 2.5 Hz, H-2’), 4.22–4.18 (m, 1H, H-4’), 3.80 (s, 3H, OCH3), 3.79
(s, 3H, OCH3), 3.55 (dd, J=11.0, 2.5 Hz, 1H, H-5’), 3.50 ppm (dd, J=
11.0, 2.5 Hz, 1H, H-5’) ; 13C NMR (125 MHz, 25 8C, CDCl3): d=163.7
(C-2), 158.7, 158.6 (CH3O-C-Ph) 151.1 (C-4), 144.4 (C-Ph), 140.3 (C-6),
135.5 (C-Ph), 135.2 (C-Ph), 130.3, 130.2, 130.1, 129.2, 128.1, 127.9,
127.8, 127.1, 113.4, 113.3, 113.2 (CH-Ph), 102.3 (C-5), 90.6 (C-1’), 83.8
(C-4’), 87.0 (C(Ph)3), 75.5 (C-2’), 69.7 (C-3’), 61.9 (C-5’), 55.2 ppm
(OCH3) ; MS (ES+) found: m/z 569.2 [M+Na]
+ , calcd for
[C30H30N2O8]: m/z 546.57 [M]; Reverse-phase HPLC (H2O/CH3CN
from 80:20 to 10:90 in 15 min, then to CH3CN 100% in 25 min),
flow=1 mLmin¢1, l=245 nm, tR=10.56 min.
5’-O-Dimetoxytrityl-N-acetyl-lamivudine (12H) was prepared ac-
cording to the general procedure 1 from N-acetyl-lamivudine (12)
(0.80 g, 2.95 mmol), 4,4’-dimethoxytrityl chloride (1.2 g, 2.95 mmol),
and DMAP (0.036 g, 0.295 mmol) in anhydrous pyridine (5 mL).
Column chromatography with a gradient of MeOH/triethylamine
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(1:0.5% to 2:0.5%) in CH2Cl2 as an eluent yielded 12H as a white
solid (0.55 g, 33%); 1H NMR (500 MHz, 25 8C, CDCl3): d= 9.73 (bs,
1H, NH), 8.43 (d, J=7.5 Hz, 1H, H-6), 7.49–7.47 (m, 2H, H-Ph), 7.38–
7.29 (m, 7H, H-Ph), 7.21 (d, J=7.5 Hz, H-5), 6.90–6.88 (m, 4H, H-Ph),
6.37 (dd, J=5.5, 2.0 Hz, 1H, H-1’), 5.34 (t, J=5.0 Hz, 1H, H-4’), 3.84
(s, 6H, OCH3), 3.68 (dd, J=12.5, 2.5 Hz, 1H, H-5’a), 3.64–3.60 (m,
2H, H-5’b and H-2’a), 3.29 (d, J=12.5 Hz, H-2’b), 2.27 ppm (s, 3H,
CH3) ;
13C NMR (125 MHz, 25 8C, CDCl,): d=170.5 (COCH3), 163.0
(C-2), 158.7 (CH3O-C-Ph), 154.9 (C-4), 145.7 (C-5), 145.3 (C-Ph), 135.3,
135.1 (C-Ph), 128.4, 128.1, 113.7, (CH-Ph), 87.9 (C-5), 87.6 (CH-1’),
87.3 (C(Ph)3), 63.5 (CH2-5’), 55.3 (OCH3), 39.7 (CH2-2’), 24.9 ppm
(COCH3) ; MS (ES+) found: m/z 596.2 [M+Na]
+ , calcd for
[C31H31N3O6S]: m/z 573.1974 [M]; Reverse-phase HPLC (H2O/CH3CN
from 80:20 to 0:100 in 30 min), flow=1 mLmin¢1, l=254 nm, tR=
21.59 min.
5’-O-Trityl-5-iodo-2’-deoxyuridine (14D) was prepared according
to the general procedure 1 from 5-iodo-2’-deoxyuridine (14) (0.5 g,
1.41 mmol), trityl chloride (1.26 g, 4.52 mmol), and DMAP (0.172 g,
1.41 mmol) in anhydrous pyridine (10 mL). Column chromatogra-
phy eluting with a gradient of MeOH (1% to 4%) in CH2Cl2 gave
5’-O-trityl-5-iodo-2’-deoxyuridine (14D) as a white solid (0.46 g,
55%); 1H NMR (500 MHz, 25 8C, CDCl3): d=9.34 (bs, 1H, NH), 8.16
(s, 1H, H-6), 7.47–7.46 (m, 6H, H-Ph), 7.36–7.33 (m, 6H, H-Ph), 7.29–
7.26 (m, 3H, H-Ph), 6.34 (dd, J=6.0, 8.0 Hz, 1H, H-1’), 4.58–4.57 (m,
1H, H-3’), 4.15–4.13 (m, 1H, H-4’), 3.45–3.39 (m, 2H, H-5’), 2.56–2.52
(m, 1H, H-2’a), 2.32–2.28 ppm (m, 1H, H-2’b); 13C NMR (125 MHz,
25 8C, CDCl3): d=160.0 (C-2), 149.7 (C-4), 144.2 (C-6), 143.3 (C-Ph),
128.6, 128.1, 127.4 (CH-Ph), 88.3 (C-5), 87.7 (C(Ph)3), 86.3 (C-4’), 85.5
(C-1’), 72.3 (C-3’), 63.6 (C-5’), 49.5 ppm (C-2’) ; MS (ES+) found: m/z
619.2 [M+Na]+ , calcd for [C28H25IN2O5] m/z 596.4130 [M]; Reverse-
phase HPLC (H2O/CH3CN from 80:20 to 0:100 in 30 min), flow=
1 mLmin¢1, l=254 nm, tR=20.71 min.
Dimethoxytritylated derivatives of 5-fluoro-2’deoxyuridine (15)
were prepared according to the general procedure 1 from 15
(0.30 g, 1.22 mmol) and 4,4’-dimethoxytrityl chloride (0.90 g,
2.68 mmol) in pyridine (6 mL). Column chromatography purifica-
tion using gradient of MeOH/triethylamine (1:0.5% to 2:0.5%) in
CH2Cl2 as an eluent followed by preparative TLC purification with
MeOH/triethylamine (2:0.5%) in CH2Cl2 yielded 5’,3’-bis-O-dime-
thoxytrityl-5-fluoro-2’-deoxyuridine (15F) and 5’-O-dimethoxytrityl-
5-fluoro-2’-deoxyuridine (15H).
5’-O-Dimethoxytrityl-5-fluoro-2’-deoxyuridine (15H) was ob-
tained as a yellowish solid (0.135 g, 20%); 1H NMR (500 MHz, 25 8C,
MeOD): d=7.92 (d, JH¢F=6.5 Hz, 1H, H-6), 7.45 (dd, J=9.0, 1.5 Hz,
2H, H-Ph), 7.35–7.29 (m, 6H, H-Ph), 7.25–7.23 (m, 1H, H-Ph), 6.89–
6.87 (m, 4H, H-Ph), 6.25–6.22 (m, 1H, H-1’), 4.52–4.49 (m, 1H, H-3’),
4.05–4.03 (m, 1H, H-4’), 3.80 (s, 6H, 2 x OCH3), 3.42 (dd, J=10.5,
4.0 Hz, 1H, H-5’), 3.35 (dd, J=10.5, 4.0 Hz, 1H, H-5’), 2.43–2.38 (m,
1H, H-2’), 2.35–2.29 ppm (m, 1H, H-2’) ; 13C NMR (125 MHz, 25 8C,
CDCl3): d=160.6 (C-2), 158.7 (CH3O-C-Ph), 156.7 (C-4), 144.8 (C-Ph),
143.4 (d, 1JC¢F=239.5 Hz, C-5), 129.8, 128.8, (CH-Ph), 124.3 (d,
2JC¢F=32.8 Hz, C-6), 113.7 (CH-Ph), 88.7 (C(Ph)3), 87.8 (C-1’), 87.0 (C-
4’), 72.3 (C-3’), 63.9 (C-5’), 55.3 (OCH3), 40.7 ppm (C-2’) ; MS (ES+)
found: m/z 571.6 [M+Na]+ , calcd for [C30H29FN2O7]: m/z 548.55
[M]; Reverse-phase HPLC (H2O/CH3CN from 90:10 to 0:50 in
30 min), flow=1 mLmin¢1, l=245 nm, tR=18.44 min.
Tritylated derivatives of 2’-fluoro-2’-deoxyuridine (16) were pre-
pared according to the general procedure 1 from 16 (0.50 g,
2.03 mmol) and trityl chloride (1.60 g, 5.69 mmol) in anhydrous pyr-
idine (10 mL). After work-up, the crude sample was purified by
column chromatography using gradient of MeOH/triethylamine
(1:0.5% to 2.5:0.5%) in CH2Cl2 to give 5’,3’-bis-O-trityl-2’-fluoro-2’-
deoxyuridine 16B and 5’-O-trityl-2’-fluoro-2’-deoxyuridine 16D.
5’-O-Trityl-2’-fluoro-2’-deoxyuridine (16D) was obtained as
a white solid (0.79 g, 80%); 1H NMR (500 MHz, 25 8C, [D6]DMSO):
d=11.43 (bs, 1H, NH), 7.77 (d, J=8.1 Hz, 1H, H-6), 7.41–7.29 (m,
15H, H-Ph), 5.91–5.87 (m, 1H, H-1’), 5.70–5.69 (m, 1H, OH-3’), 5.31
(d, J=8.1 Hz, 1H, H-5), 5.18–5.07 (m, 1H, H-2’), 4.41–4.32 (m, 1H,
H-3’), 4.03–4.00 (m, 1H, H-4’), 3.34–3.28 ppm (m, 2H, H-5’) ; 13C NMR
(125 MHz, 25 8C, [D6]DMSO): d=163.1 (C-4), 150.0 (C-2), 143.3
(‘ipso’ C-Ph), 140.8 (C-6), 128.3, 127.9, 127.2 (CH-Ph), 101.4 (C-5),
93.4 (d, JC-F=184.5 Hz, C-2’), 88.6 (d, JC-F=35.7 Hz, C-1’), 86.3
(C(Ph)3), 80.8 (C-4’), 67.9 (d, JC-F=16.6 Hz, C-3’), 62.2 ppm (C-5’) ;
19F NMR ([D6]DMSO, 470 MHz): d=¢199.47 ppm; MS (ES+) found:
m/z 511.14 [M+Na]+ , calcd for [C28H25FN2O5]: m/z 488.51 [M]; Re-
verse-phase HPLC (H2O/CH3CN from 50:50 to 0:100 in 30 min),
flow=1 mLmin¢1, l=254 nm, tR=6.35 min.
Dimethoxytritylated derivatives of 2’-fluoro-2’-deoxyuridine (16)
were prepared according to the general procedure 1 from 16
(0.200 g, 0.81 mmol), 4,4’-dimethoxytrityl chloride (0.769 g,
2.27 mmol), and DMAP (0.278 g, 2.27 mmol) in anhydrous pyridine
(10 mL). After work-up, the crude sample was purified by column
chromatography using gradient of MeOH/triethylamine (1:0.5% to
2.5:0.5%) in CH2Cl2 to give 5’,3’-bis-O-dimethoxytrityl-2’-fluoro-2’-
deoxyuridine (16F) and 5’-O-dimethoxytrityl-2’-fluoro-2’-deoxyuri-
dine (16H).
5’-O-Dimethoxytrityl-2’-fluoro-2’-deoxyuridine (16H) was ob-
tained as a white solid (0.053 g, 12%); 1H NMR (500 MHz, 25 8C,
CDCl3): d=7.91 (d, J=8.5 Hz, 1H, H-6), 7.41–7.38 (m, 2H, Ar), 7.35–
7.25 (m, 8H, H-Ph), 6.89–6.85 (m, 3H, H-Ph), 6.09 (dd, J=16.5,
1.5 Hz, 1H, H-1’), 5.36 (d, J=8.5 Hz, 1H, H-5), 5.05 (dddd, J=52.5,
4.5, 1.5 Hz, 1H, H-2’), 4.55 (dddd, J=20.0, 8.0, 4.0, Hz, 1H, H-3’),
4.13–4.08 (m, 1H, H-4’), 3.83 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.66
(dd, J=11.5, 2.5 Hz, 1H, H-5’), 3.55 ppm (dd, J=11.5, 2.5 Hz, 1H, H-
5’) ; 13C NMR (125 MHz, 25 8C, CDCl3): d=162.4 (C-2), 158.8, 158.7
(CH3O-C-Ph), 149.7 (C-4), 144.2 (C-Ph), 139.8 (C-6), 135.1, 135.0 (C-
Ph), 130.2, 130.1, 128.2, 128.1, 127.2, 113.4 (CH-Ph), 102.5 (C-5), 93.9
(d, 1JCF=185.7 Hz, C-2’), 87.6 (d,
2JCF=33.6 Hz, C-1’), 82.3 (C-4’), 87.0
(C(Ph)3), 69.1 (d,
2JCF=17.0 Hz, C-3’), 61.1 (C-5’), 55.3 ppm (OCH3) ;
MS (ES+) found: m/z : 571.2 [M+Na]+ , calcd for [C30H29FN2O7]: m/z
548.56 [M]; Reverse-phase HPLC (H2O/CH3CN from 80:20 to 10:90
in 15 min, then to CH3CN 100% in 25 min, flow=1 mLmin
¢1, l=
245 nm, tR=11.64 min.
Tritylated derivatives of 5-methyluridine (19) were prepared ac-
cording to general procedure 1 from 19 (0.50 g, 1.94 mmol) and
trityl chloride (1.50 g, 5.42 mmol) in anhydrous pyridine (8.0 mL).
Column chromatography using a gradient of MeOH/triethylamine
(1:0.5% to 2:0.5%) in CH2Cl2 as eluent yielded 5’,3’-bis-O-trityl-5-
methyluridine (19B), 5’,2’-bis-O-trityl-5-methyluridine (19C) and 5’-
O-trityl-5-methyluridine (19D).
5’-O-Trityl-5-methyl-uridine (19D) was obtained as a white solid
(0.36 g, 37%); 1H NMR (500 MHz, 25 8C, [D6]DMSO): d=11.38 (bs,
1H, NH), 7.50–7.27 (m, 16H, H-Ph, H-6), 5.81 (d, J=5.2 Hz, 1H, H-
1’), 5.49 (d, J=5.7 Hz, 1H, OH-2’), 5.19 (d, J=5.6 Hz, 1H, OH-3’),
4.21–4.17 (m, 1H, H-2’), 4.14–4.11 (m, 1H, H-3’), 3.98–3.96 (m, 1H,
H-4’), 3.28–3.16 (m, 2H, H-5’), 1.44 ppm (d, J=1.1 Hz, 3H, CH3) ;
13C NMR (125 MHz, 25 8C, [D6]DMSO): d=163.6 (C-4), 150.6 (C-2),
143.4 (‘ipso’ C-Ph), 135.8 (C-6), 128.2, 128.0, 127.1 (CH-Ph), 109.4 (C-
5), 88.0 (C-1’), 86.4 (C(Ph)3), 82.7 (C-4’), 73.0 (C-2’), 70.0 (C-3’), 63.7
(C-5’), 11.6 ppm (CH3) ; MS (ES+) found: m/z 523.16 [M+Na]
+ ,
calcd for [C29H28N2O6]: m/z 500.54 [M]; Reverse-phase HPLC (H2O/
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CH3CN from 95:5 to 0:100 in 30 min), flow=1 mLmin
¢1, l=
254 nm, tR=20.36 min.
Tritylated derivatives of fludarabine (20) were prepared according
to the standard procedure 1 from 20 (0.30 g, 1.05 mmol) and trityl
chloride (0.64 g, 2.31 mmol) in pyridine (6 mL). Column chromatog-
raphy purification using a gradient of MeOH/triethylamine (1:0.5%
to 2:0.5%) in CH2Cl2 as eluent gave two products which were fur-
ther repurified by preparative TLC with MeOH/triethylamine
(2:0.5%) in CH2Cl2 to yield 5’, 3’-bis-O-trityl-fludarabine (20B) and
5’-O,N-trityl-fludarabine (20D-NHTr).
5’-Bis-O,N-trityl-fludarabine (20D-NHTr) was obtained as a white
solid (0.05 g, 6%); 1H NMR (500 MHz, 25 8C, CDCl3): d=8.16 (s, 1H,
H-8), 7.45–7.33 (m, 8H, H-Ph), 7.38–7.36 (m, 8H, H-Ph), 7.38–7.36
(m, 14H, H-Ph), 6.18 (d, J=3.5 Hz, 1H, H-1’), 4.36 (apparent broad
d, J=2.5 Hz, 1H, H-3’), 4.25–4.20 (m, 2H, H-2’, NH), 4.05 (q, J=
3.5 Hz, 1H, H-4’), 3.89 (bs, 1H, 3’-OH), 3.62 (dd, J=11.0, 3.0 Hz, 1H,
H-5’), 3.42 ppm (dd, J=11.0, 3.0 Hz, 1H, H-5’) ; 13C NMR (125 MHz,
25 8C, CDCl3): d=159.9 (
1JC¢F=209.0 Hz, C-2), 155.7 (
3JC¢F=20.8 Hz,
C-6), 149.3 (3JC¢F=18.0 Hz, C-4), 144.2, 142.9 (C-Ph), 140.1 (CH-8),
129.0, 128.6, 128.1, 127.9, 127.5, 127.1 (CH-Ph), 118.8 (4JC¢F=3.8 Hz,
C-5), 88.2, 88.1 (C(Ph)3), 85.1 (C-1’), 83.0 (C-4’), 76.7 (C-3’), 76.6 (C-2’),
63.6 ppm (C-5’) ; 19F NMR (470 MHz, 25 8C, CDCl3): d=¢49.84; MS
(ES+) found: m/z 792.3 [M+Na]+ , calcd for [C48H40FN5O4]: m/z
769.86 [M]; Reverse-phase HPLC (H2O/CH3CN from 90:10 to 0:50 in
30 min), flow=1 mLmin¢1, l=245 nm, tR=27.40 min.
Tritylated derivatives of thymidine (21) were prepared according to
the general procedure 1 from 21 (0.30 g, 1.24 mmol) and trityl
chloride (0.75 g, 2.72 mmol) in pyridine (6 mL). Column chromatog-
raphy using a gradient of MeOH/triethylamine (1:0.5% to 3:0.5%)
in CH2Cl2 as an eluent gave 5’,3’-bis-O-trityl-thymidine (21B) and
5’-O-trityl-thymidine (1).
5’,3’-Bis-O-trityl-thymidine (21B) was obtained as a white solid
(0.147 g, 16%); 1H NMR (500 MHz, 25 8C, CDCl3): d=7.53 (d, J=
1.0 Hz, 1H, H-6), 7.41–7.39 (m, 6H, H-Ph), 7.27–7.23 (m, 24H, H-Ph),
6.47 (t, J=7.5 Hz, 1H, H-1’), 4.45–4.42 (m, 1H, H-3’), 3.87–3.85 (m,
1H, H-4’), 3.24 (dd, J=11.0, 2.5 Hz, 1H, H-5’), 2.86 (dd, J=11.0,
2.5 Hz, 1H, H-5’), 1.97–1.94 (m, 2H, H-2’), 1.41 ppm (d, J=1.0 Hz,
3H, CH3) ;
13C NMR (125 MHz, 25 8C, CDCl3): d=163.3 (C=O, C-2),
150.1 (C=O, C-4), 144.0, 143.3 (C-Ph), 135.8 (C-6), 129.0, 128.7,
128.5, 128.2, 128.0, 127.9, 127.4, 127.3, 125.3 (CH-Ph), 111.0 (C-5),
87.8, 87.4 (C(Ph)3), 85.4 (C-4’), 84.9 (C-1’), 75.4 (C-3’), 63.8 (C-5’), 39.7
(C-2’), 11.7 ppm (CH3) ; MS (ES+) found: m/z 749.38 [M+Na]
+ ,
calcd for [C48H42N2O5]: m/z 726.85 [M]; Reverse-phase HPLC (H2O/
CH3CN from 90:10 to 0:50 in 30 min), flow=1 mLmin
¢1, l=
245 nm, tR=24.56 min.
5’-O-Trityl-thymidine (1) was obtained as a white solid (0.19 g,
33%); 1H NMR (500 MHz, 25 8C, [D6]DMSO): d=7.50 (d, J=1.0 Hz,
1H, H-6), 7.41–7.38 (m, 6H, H-Ph), 7.36–7.33 (m, 6H, H-Ph), 7.30–
7.26 (m, 3H, H-Ph), 6.21 (t, J=6.5 Hz, 1H, H-1’), 5.30 (d, J=4.5 Hz,
C-3’-OH), 4.35–4.31 (m, 1H, H-3’), 3.90–3.88 (m, 1H, H-4’), 3.24 (dd,
J=10.5, 3.0 Hz, 1H, H-5’), 3.17 (dd, J=10.5, 3.0 Hz, 1H, H-5’), 2.29-
2.23 (m, 1H, H-2’), 2.18–2.13 (m, 1H, H-2’), 1.47 ppm (d, J=1.0 Hz,
3H, CH3) ;
13C NMR (125 MHz, 25 8C, [D6]DMSO): d=163.6 (C=O,
C-2), 150.3 (C=O, C-4), 143.4, (C-Ph), 135.6 (C-6), 128.2, 127.9, 127.1
(CH-Ph), 109.5 (C-5), 86.3 (C(Ph)3), 85.3 (C-4’), 83.6 (C-1’), 70.4 (C-3’),
63.9 (C-5’), 40.0 (C-2’), 11.7 ppm (CH3) ; MS (ES+) found: m/z 507.54
[M+Na]+ , calcd for [C29H28N2O5]: m/z 484.54 [M]; Reverse-phase
HPLC (H2O/CH3CN 90:10 to 0:50 in 30 min), flow=1 mLmin
¢1, l=
245 nm, tR=6.29 min.
Tritylated derivatives of penciclovir (22) were prepared according
to general procedure 1 from 22 (0.57 g, 2.25 mmol) and trityl chlo-
ride (1.86 g, 6.75 mmol) in anhydrous pyridine (10 mL). Column
chromatography eluting using a gradient of MeOH/triethylamine
(1:0.5% to 3:0.5%) in CH2Cl2 yielded 5’,3’-bis-O-trityl-penciclovir
(22B) and 2-N,5’,3’-O-tri-trityl penciclovir (22B-NHTr).
2-N-5’,3’-O-Tri-trityl penciclovir (22B-NHTr) was obtained as
a white solid (0.47 g, 21%); 1H NMR (500 MHz, 25 8C, [D6]DMSO):
d=10.51 (bs, 1H, NH), 7.26 (s, 1H, H-8), 7.31–7.28 (m, 31H, H-Ph,
NH), 7.19–7.17 (m, 6H, H-Ph), 7.07–7.04 (m, 6H, H-Ph), 6.97–6.96
(m, 3H, H-Ph), 3.24–3.21 (m, 2H, H-1’), 2.91–2.85 (m, 4H, H-4’, H-5’),
1.62–1.58 (m, 1H, H-3’), 1.13–1.09 ppm (m, 2H, H-2’) ; 13C NMR
(125 MHz, 25 8C, [D6]DMSO): d=156.5 (C-6), 150.3 (C-2), 149.3 (C-4),
144.6, 143.8 (‘ipso’ C-Ph), 137.2 (C-8), 128.7, 128.4, 128.1, 127.8,
127.4, 126.9, 126.3 (CH-Ph), 117.0 (C-5), 85.8 (C(Ph)3), 62.7 (C-4’, C-
5’), 41.3 (C-1’), 37.3 (C-3’), 28.4 ppm (C-2’) ; MS (ES+) found: m/z
1003.39 [M+Na]+ , calcd for [C67H57N5O3] m/z : 980.20 [M]; Reverse-
phase HPLC (H2O/CH3CN from 50:50 to 0:100 in 40 min), flow=
1 mLmin¢1, l=254 nm, tR=36.64 min.
Biological assays
Antiviral assay : Trityl compounds were prepared as stock solution
of 100 mm in dimethyl sulfoxide (DMSO) and then were diluted to
a final assay concentration of 20, 10, 5 mm. Dilutions were made by
adding the appropriate amount of DMSO to lyophilized compound
to achieve stock concentrations of 10 to 100 mm. Dissolved com-
pounds were stored at ¢20 8C and brought to rt prior to assay. All
compounds were well dissolved in DMSO, and precipitates were
not observed upon thawing.
Cell culture : Vero cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM, Sigma-Aldrich) with 10% FBS (Sigma-Aldrich).
Cells were plated into 96-well plates at a density of 103 cells per
well.
Virus culture : Cells were then infected with dengue virus (serotype
D2 (strain New Guinea C), ATCC Number: VR-1584), and yellow
fever vaccine (17D strain Asibi; grown from a dose of Sanofi Pas-
teur STAMARIL (1000IU from embryonated chicken eggs) and
adapted to Vero cells (Farleigh and Bugert, 2014, unpublished re-
sults) at a moi of 1, or left uninfected to determine compound tox-
icity.
Cell viability was determined after seven days using CellTiterGlo
PROMEGA, following the manufacturer’s instructions. All experi-
ments were performed in triplicate.
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